Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

Nilotinib, a 2 nd generation tyrosin kinase inhibitor (TKI), is efficacious in the treatment of chronic myelogenous leukemia (CML). 1 Impaired glucose metabolism with hyperglycemia represents one of the most frequently observed adverse events (AEs) during nilotinib therapy. 1 However, the mechanism of glucose metabolism impairment remains unknown.